On this page of StockholderLetter.com we present the latest annual shareholder letter from DiaMedica Therapeutics Inc. — ticker symbol DMAC. Reading current and past DMAC letters to shareholders can bring important insights into the investment thesis.
2025 Annual Report & 2026 Annual General Meeting Proxy Statement
Dear Shareholders: 2025 was a year of continued execution and strategic progress for DiaMedica as we advanced DM199 (rinvecalinase alfa) across preeclampsia (PE) and acute ischemic stroke (AIS). Our focus remains clear: x generate high-quality clinical data; x de-risk development; and x position DM199 for late-stage success while maintaining disciplined capital management. Preeclampsia Program During the year, we advanced our PE program into clinical development, marking an important expansion of DM199 s potential. Recently, we received a No Objection Letter from Health Canada, enabling initiation of a DiaMedica-sponsored Phase 2 study in early-onset PE. The Phase 2 study is designed as a dose-ranging trial to inform Phase 3 dose selection, while also evaluating safety, pharmacokinetics, and preliminary efficacy signals. We are particularly focused on demonstrating that DM199 does not cross the placental barrier, a key safety consideration, alongside clinically meaningful outcomes such as prolongation of pregnancy and maternal health measures. Preeclampsia represents a significant unmet medical need with limited treatment options, and we believe DM199 s mechanism represents a novel approach to improving outcomes for both mothers and infants. Progress in the ReMEDy2 Trial We made meaningful progress in our ReMEDy2 Phase 2/3 pivotal trial in AIS. Following prior protocol refinements designed to enhance patient selection and safety, we continued expanding our clinical footprint and improving site activation which has led to our recent improvements in study enrollment. Our engagement with investigators and focus on operational execution have positioned the study to advance steadily. AIS remains a large and underserved market, and we believe DM199 s differentiated mechanism continues to support its potential as a meaningful therapeutic option. We remain focused on disciplined trial execution and generating robust data to support future regulatory interactions. Leadership and Organizational Strength Our team remains a core strength of the company. We have maintained a disciplined and experienced organization with deep expertise in clinical development, regulatory strategy, and execution. Our Board of Directors and leadership team remain focused on advancing our programs efficiently while maintaining high standards of scientific rigor.
We also expanded our Board of Directors with the addition of Dan O Connor. Dan brings a wealth of experience from his leadership at Ambryx Biopharma Inc., which was acquired by Johnson & Johnson in 2024. His strategic vision and deep industry knowledge will be invaluable as we continue to grow and execute our mission. Financial Stability and Growth We ended the year with a solid financial position and have maintained a runway that supports our current operating plan through the end of 2027. We continue to prioritize capital efficiency while advancing our clinical programs and evaluating strategic opportunities to strengthen our balance sheet and support long-term value creation. Looking Ahead As we move forward, our priorities are clear: advance ReMEDy2, execute our Phase 2 PE study with a focus on Phase 3 dose selection, and continue generating data to support regulatory pathways. We believe these efforts position DiaMedica for important value inflection points. While drug development inherently carries risk, we are encouraged by the progress we have made and the opportunities ahead. Our team remains committed to disciplined execution and to advancing DM199 with the goal of delivering meaningful therapies to patients in need. We thank our shareholders for their continued support and confidence. Sincerely, James Parsons Chairman of the Board Rick Pauls President and Chief Executive Officer
 • shareholder letter icon 4/1/2026 Letter Continued (Full PDF)
 • stockholder letter icon 4/4/2023 DMAC Stockholder Letter
 • stockholder letter icon 4/4/2024 DMAC Stockholder Letter
 • stockholder letter icon 3/28/2025 DMAC Stockholder Letter
 • stockholder letter icon More "Biotechnology" Category Stockholder Letters
 • Benford's Law Stocks icon DMAC Benford's Law Stock Score = 83


DMAC Shareholder/Stockholder Letter Transcript:

2025 Annual Report &
2026 Annual General
Meeting Proxy Statement


Dear Shareholders:
2025 was a year of continued execution and strategic progress for DiaMedica as we advanced
DM199 (rinvecalinase alfa) across preeclampsia (PE) and acute ischemic stroke (AIS). Our focus
remains clear:
x
generate high-quality clinical data;
x
de-risk development; and
x
position DM199 for late-stage success while maintaining disciplined capital management.
Preeclampsia Program
During the year, we advanced our PE program into clinical development, marking an important
expansion of DM199   s potential. Recently, we received a    No Objection    Letter from Health
Canada, enabling initiation of a DiaMedica-sponsored Phase 2 study in early-onset PE.
The Phase 2 study is designed as a dose-ranging trial to inform Phase 3 dose selection, while also
evaluating safety, pharmacokinetics, and preliminary efficacy signals. We are particularly focused on
demonstrating that DM199 does not cross the placental barrier, a key safety consideration, alongside
clinically meaningful outcomes such as prolongation of pregnancy and maternal health measures.
Preeclampsia represents a significant unmet medical need with limited treatment options, and we
believe DM199   s mechanism represents a novel approach to improving outcomes for both mothers
and infants.
Progress in the ReMEDy2 Trial
We made meaningful progress in our ReMEDy2 Phase 2/3 pivotal trial in AIS. Following prior
protocol refinements designed to enhance patient selection and safety, we continued expanding our
clinical footprint and improving site activation which has led to our recent improvements in study
enrollment. Our engagement with investigators and focus on operational execution have positioned
the study to advance steadily.
AIS remains a large and underserved market, and we believe DM199   s differentiated mechanism
continues to support its potential as a meaningful therapeutic option. We remain focused on
disciplined trial execution and generating robust data to support future regulatory interactions.
Leadership and Organizational Strength
Our team remains a core strength of the company. We have maintained a disciplined and experienced
organization with deep expertise in clinical development, regulatory strategy, and execution. Our
Board of Directors and leadership team remain focused on advancing our programs efficiently while
maintaining high standards of scientific rigor.

We also expanded our Board of Directors with the addition of Dan O   Connor. Dan brings a wealth of
experience from his leadership at Ambryx Biopharma Inc., which was acquired by Johnson &
Johnson in 2024. His strategic vision and deep industry knowledge will be invaluable as we continue
to grow and execute our mission.
Financial Stability and Growth
We ended the year with a solid financial position and have maintained a runway that supports our
current operating plan through the end of 2027. We continue to prioritize capital efficiency while
advancing our clinical programs and evaluating strategic opportunities to strengthen our balance
sheet and support long-term value creation.
Looking Ahead
As we move forward, our priorities are clear: advance ReMEDy2, execute our Phase 2 PE study with
a focus on Phase 3 dose selection, and continue generating data to support regulatory pathways. We
believe these efforts position DiaMedica for important value inflection points.
While drug development inherently carries risk, we are encouraged by the progress we have made
and the opportunities ahead. Our team remains committed to disciplined execution and to advancing
DM199 with the goal of delivering meaningful therapies to patients in need.
We thank our shareholders for their continued support and confidence.
Sincerely,
James Parsons
Chairman of the Board
Rick Pauls
President and Chief Executive Officer


shareholder letter icon 4/1/2026 Letter Continued (Full PDF)
 

DMAC Stockholder/Shareholder Letter (DiaMedica Therapeutics Inc.) | www.StockholderLetter.com
Copyright © 2023 - 2026, All Rights Reserved

Nothing in StockholderLetter.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy.